Passa al contenuto
Merck
Tutte le immagini(2)

Key Documents

View All Documentation

A5602

Sigma-Aldrich

AMD3100 octahydrochloride hydrate

≥97% (NMR), solid, CXCR4 antagonist

Sinonimo/i:

1,1′-[1,4-Phenylenebis(methylene)]bis-1,4,8,11-tetraazacyclotetradecane octahydrochloride, JM3100, Plerixafor, SID791

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(2)

About This Item

Formula empirica (notazione di Hill):
C28H54N8 · 8HCl · xH2O
Numero CAS:
155148-31-5
Peso molecolare:
794.47 (anhydrous basis)
Codice UNSPSC:
51111800
ID PubChem:
24724394
NACRES:
NA.77

product name

AMD3100 octahydrochloride hydrate, ≥97% (NMR), solid

Livello qualitativo

100

Saggio

≥97% (NMR)

Forma fisica

solid

Condizioni di stoccaggio

desiccated

Solubilità

H2O: ≥10 mg/mL, clear

Ideatore

Sanofi Aventis

Temperatura di conservazione

−20°C

Stringa SMILE

Cl[H].Cl[H].Cl[H].Cl[H].Cl[H].Cl[H].Cl[H].Cl[H].[H]O[H].C1CNCCNCCCN(CCNC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2

InChI

1S/C28H54N8.8ClH.H2O/c1-9-29-15-17-31-13-3-21-35(23-19-33-11-1)25-27-5-7-28(8-6-27)26-36-22-4-14-32-18-16-30-10-2-12-34-20-24-36;;;;;;;;;/h5-8,29-34H,1-4,9-26H2;8*1H;1H2
GKFHDCZYJHUPEN-UHFFFAOYSA-N

Applicazioni

AMD3100 is a highly specific chemokine receptor CXCR4 antagonist. AMD3100 has been used in a study to determine the blockade of CXCR4 in oral squamous cell carcinoma and inhibition of lymph node metastases.

Azioni biochim/fisiol

AMD3100 is a highly specific chemokine receptor CXCR4 antagonist.

Caratteristiche e vantaggi

This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Dispositivi di protezione individuale

Eyeshields, Gloves, type N95 (US)

Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 7

1 of 7

GW2580 ≥98% (HPLC)

Sigma-Aldrich

SML1047

GW2580

BRL 37344 sodium salt hydrate solid

Sigma-Aldrich

B169

BRL 37344 sodium salt hydrate

SB225002 ≥98% (HPLC)

Sigma-Aldrich

SML0716

SB225002

Supelco

Supelco

PHR1839

Amiloride Hydrochloride

SDF-1 ALPHA human Animal-component free, recombinant, expressed in E. coli, ≥98% (SDS-PAGE), ≥98% (HPLC)

Sigma-Aldrich

SRP3276

SDF-1 ALPHA human

Anti-CXCR4 antibody produced in rabbit IgG fraction of antiserum, buffered aqueous solution

Sigma-Aldrich

SAB3500383

Anti-CXCR4 antibody produced in rabbit

Neurotensin Fragment 8-13 acetate salt ≥97% (HPLC)

Sigma-Aldrich

N5266

Neurotensin Fragment 8-13 acetate salt

David H McDermott et al.
Blood, 123(15), 2308-2316 (2014-02-14)
Warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome is a rare immunodeficiency disorder caused by gain-of-function mutations in the G protein-coupled chemokine receptor CXCR4. The CXCR4 antagonist plerixafor, which is approved by the US Food and Drug Administration (FDA) for stem
Brian A Zabel et al.
Molecular cancer, 10, 73-73 (2011-06-16)
Migration of metastatic tumor cells from the bloodstream into lymph nodes is thought to be facilitated by expression of the chemokine receptors CCR7, CXCR4 and, for B cell-derived tumors, CXCR5. Expression of their respective chemokine ligands (CCL19, CCL21, CXCL12 and
Andreas Lundqvist et al.
Journal of immunology (Baltimore, Md. : 1950), 191(12), 6241-6249 (2013-11-19)
Plerixafor (Mozobil) is a CXCR4 antagonist that rapidly mobilizes CD34(+) cells into circulation. Recently, plerixafor has been used as a single agent to mobilize peripheral blood stem cells for allogeneic hematopoietic cell transplantation. Although G-CSF mobilization is known to alter
Sapna Devi et al.
The Journal of experimental medicine, 210(11), 2321-2336 (2013-10-02)
Blood neutrophil homeostasis is essential for successful host defense against invading pathogens. Circulating neutrophil counts are positively regulated by CXCR2 signaling and negatively regulated by the CXCR4-CXCL12 axis. In particular, G-CSF, a known CXCR2 signaler, and plerixafor, a CXCR4 antagonist
Kelli P A MacDonald et al.
Journal of immunology (Baltimore, Md. : 1950), 192(7), 3180-3189 (2014-03-04)
The majority of allogeneic stem cell transplants are currently undertaken using G-CSF mobilized peripheral blood stem cells. G-CSF has diverse biological effects on a broad range of cells and IL-10 is a key regulator of many of these effects. Using
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.